← Browse by Condition
Medical Condition
diffuse large b cell lymphoma dlbcl
Total Trials
4
Recruiting Now
4
Trial Phases
Phase 1, Phase 2
Lymphoma trials span diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, Hodgkin lymphoma, mantle cell lymphoma, and T-cell lymphomas β€” each with distinct biology and treatment response. CAR-T cell therapy has established a new standard in relapsed/refractory DLBCL, and trials now aim to move this approach earlier in the treatment sequence.
Active trials evaluate bispecific antibodies (mosunetuzumab, epcoritamab, glofitamab), next-generation CAR-T cell products (CD19/CD22 dual targets, BCMA-targeting), BTK inhibitors in B-cell lymphomas, and total metabolic volume on PET as a predictive biomarker for treatment adaptation.
Frequently Asked Questions — diffuse large b cell lymphoma dlbcl Clinical Trials
How many clinical trials are currently recruiting for diffuse large b cell lymphoma dlbcl?
ClinicalMetric currently tracks 4 actively recruiting clinical trials for diffuse large b cell lymphoma dlbcl, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 4. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for diffuse large b cell lymphoma dlbcl?
diffuse large b cell lymphoma dlbcl research spans Phase 1 (2 trials), Phase 2 (2 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a diffuse large b cell lymphoma dlbcl clinical trial?
Eligibility criteria for diffuse large b cell lymphoma dlbcl trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1 2
Phase 2 2
Top Sponsors
1 trial
1 trial
1 trial
1 trial
Recruiting Clinical Trials
NCT05107674 Phase 1
Recruiting
Enrollment
345 pts
Location
United States, Unite...
Sponsor
Nurix Therapeutics, Inc.
NCT06464861 Phase 1
Recruiting
Enrollment
52 pts
Location
China
Sponsor
Second Affiliated Hospital, Zh...
NCT07493148 Phase 2
Recruiting
Enrollment
50 pts
Location
China
Sponsor
Ou Bai, MD/PHD
NCT06828991 Phase 2
Recruiting
Enrollment
40 pts
Location
United States
Sponsor
Danielle Wallace
Related Conditions
ovarian cancer epithelial (1) gastric cancer (1) gastroesophageal junction gej cancer (1) head and neck squamous cell carcinoma (1) metastatic or unresectable melanoma (1) non small cell lung cancer nsclc (1) metastatic castration resistant prostate cancer mcrpc (1) malignant pleural mesothelioma mpm (1) triple negative breast cancer tnbc (1) metastatic urothelial carcinoma (1) cervical cancer (1) richter transformation (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology